- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00304317
Celecoxib (Celebrex) in the Management of Acute Renal Colic
January 23, 2017 updated by: University of Minnesota
Celecoxib in the Management of Acute Renal Colic
The purpose of this trial is to quantify the amount Celebrex, a specific cyclooxygenase-2 (COX-2) inhibitor, when used for the management of acute renal colic for a ureteral stone will:
- reduce pain medication usage
- improve the percentage of spontaneous stone passage
- decrease the time to spontaneous passage, and
- shift the size distribution of stones passed towards larger sizes
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
The study will be conducted as a prospective, randomized, double-blind controlled clinical trial.
One-hundred and fifty-four patients with symptoms of acute renal colic and a ureteral calculus less than 10 mm in largest diameter on flat plain abdominal x-ray (KUB) or non-contrast computer tomography (CT) scan will be randomized in this trial.
At the time of presentation with acute renal colic to the Emergency Department, the patient will be recruited for involvement.
After informed consent, patients will be provided either 200 mg of Celebrex or a placebo equivalent.
They will be instructed to follow the recommended dosing regimen for acute pain, taking two tablets in the emergency room (400 mg), followed by one tablet 12 hours later (200 mg), then one tablet twice a day for 10 days.
Patients will be provided a prescription for Vicodin (1-2 tablets of 5/500 every 4-6 hours) to be taken as required for pain.
Throughout the study, patients will be asked to strain urine for passage of calculus and note date and time of passage.
Patients will also be asked to maintain a daily narcotic diary and complete a daily pain analog scale provided by our institution.
Patients will be followed in the Urology Department's Stone Clinic with weekly imaging studies (KUB or CT scan) and renal function tests (serum creatinine) for 4 weeks.
Study Type
Interventional
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ureteral calculus <= 10 mm in largest diameter
- Patient elects conservative management over immediate surgical intervention
Exclusion Criteria:
- Solitary kidney
- Renal insufficiency (creatinine [CR] > 1.8)
- Urinary infection (fever > 101 degrees Fahrenheit, positive urine culture, many bacteria on urinalysis)
- Allergic-type reactions to sulfonamides
- Patients with known hypersensitivity to celecoxib
- Patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or nonsteroidal anti-inflammatory agents (NSAIDs)
- Prior history of gastrointestinal (GI) bleed or active gastric ulcer disease
- Pregnancy/nursing
- Moderate-severe hepatic dysfunction (Child-Pugh Classification B or C)
- Concomitant use of drugs that inhibit P450 2C9, drugs metabolized by P450 2D6, ACE inhibitors, furosemide, warfarin (and other anticoagulants, not including low-dose aspirin), fluconazole, or lithium
- Women of child-bearing age unwilling to use effective contraception for the duration of the trial.
Significant or unstable cardiovascular disease defined as:
- myocardial infarction or stroke less than 3 months prior to the study randomization
- planned revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass surgery [CABG]) at the time of study screening
- angina at rest or uncontrolled angina
- hospitalization or emergency department visits for cardiac-related illness less than 3 months prior to randomization
- uncontrolled hypertension (defined as systolic blood pressure [BP] > 140 mmHg and/or diastolic BP > 90 mmHg at the baseline visit)
- evidence of cardiac electrophysiologic instability including history of uncontrolled complex ventricular arrhythmia, uncontrolled atrial fibrillation or flutter, or uncontrolled supraventricular tachycardias with a ventricular response heart rate of > 100 beats per minute (BPM) at rest. (Subjects whose cardiac electrophysiologic instability is controlled with a pacemaker or implantable cardioverter defibrillator (ICD) are eligible.)
- symptoms, signs or treatment for congestive heart failure (CHF) or known left ventricular dysfunction with ejection fraction < 40%
- undergone coronary bypass surgery or any major surgery (cardiac or noncardiac) or trauma within the past 3 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: I
Celecoxib
|
Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.
Other Names:
|
Placebo Comparator: II
Placebo
|
Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Decrease in narcotic usage
Time Frame: at 48 hours
|
at 48 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Increase in the percentage of spontaneous stone passage
Time Frame: 6 weeks
|
6 weeks
|
Shift in the size distribution of stones passed towards larger sizes
Time Frame: 6 weeks
|
6 weeks
|
Decrease in the time to spontaneous passage
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Manoj Monga, MD, University of Minnesota
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2006
Primary Completion (Actual)
August 1, 2008
Study Completion (Actual)
August 1, 2008
Study Registration Dates
First Submitted
March 16, 2006
First Submitted That Met QC Criteria
March 16, 2006
First Posted (Estimate)
March 17, 2006
Study Record Updates
Last Update Posted (Estimate)
January 24, 2017
Last Update Submitted That Met QC Criteria
January 23, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urologic Diseases
- Pain
- Neurologic Manifestations
- Pathological Conditions, Anatomical
- Ureteral Diseases
- Urolithiasis
- Urinary Calculi
- Renal Colic
- Calculi
- Ureteral Calculi
- Ureterolithiasis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Celecoxib
Other Study ID Numbers
- 0405M60562
- 3485B
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ureteral Calculi
-
Seoul National University HospitalCompletedKidney Calculi; Ureteral CalculiKorea, Republic of
-
JW PharmaceuticalCompletedUreteral StoneKorea, Republic of
-
University of Sao Paulo General HospitalCompleted
-
Mansoura UniversityUnknownUrolithiasis | Ureteral Stone
-
Albert Einstein Healthcare NetworkTerminatedUreterolithiasis | Ureteral Stone | Ureteral CalculusUnited States
-
University Hospital, Clermont-FerrandCompletedUreteral Calculi, Hyperalgic, Not ComplicatedFrance
-
Ankara Training and Research HospitalCompletedUreterolithiasis | Ureter Stone | Ureter CalculiTurkey
-
Indiana Kidney Stone InstituteUniversity of Washington; VA Puget Sound Health Care SystemCompleted
-
Assiut UniversityCompletedUreteral Stones
-
University of Sao PauloUnknown
Clinical Trials on celecoxib
-
Chong Kun Dang PharmaceuticalCompletedOsteoarthritis HandKorea, Republic of
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedHealthy VolunteersSingapore
-
Yooyoung Pharmaceutical Co., Ltd.CliPS Co., LtdCompletedOsteoarthritis, KneeKorea, Republic of
-
Samsung Medical CenterThe Korean Urological AssociationWithdrawnBenign Prostatic HyperplasiaKorea, Republic of
-
Yooyoung Pharmaceutical Co., Ltd.CliPSBnCRecruitingOsteoarthritis, KneeKorea, Republic of
-
Seoul National University HospitalCompletedIntracerebral HemorrhageKorea, Republic of
-
Dr. Reddy's Laboratories LimitedCompleted
-
Xintian PharmaceuticalNot yet recruiting
-
Amsterdam UMC, location VUmcNetherlands Brain FoundationRecruitingInflammation | Depressive Disorder, MajorNetherlands
-
Targeted Therapy Technologies, LLCRecruitingMacula Edema | Epiretinal Membrane | Branch Retinal Vein Occlusion | Radiation Retinopathy | Central Serous Retinopathy With Pit of Optic Disc | Commotio Retinae | VitritisUnited States